



Vivimed

13.08.2011

To
National Stock Exchange of India Ltd.
Exchange Plaza,
Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E)
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Ref: Clause 41 of the Listing Agreement

With reference to the aforementioned subject and pursuant to the Clause 41 of the Listing Agreement entered into with the Stock Exchange, we are hereby forwarding unaudited stand alone and consolidated financial results for the quarter ended on June 30, 2011 approved by the Board of Directors at their Meeting held on August 13, 2011.

Highlights of consolidated results are as follows :

- Net Sales have gone up by 41.84% on YoY basis.
- Profit after Tax have gone up by 26.28% on YoY basis.



Vivimed

Board has also taken following decision.


- Approved calling for Extra Ordinary General Meeting on September 7, 2011, to seek shareholder approval for preferential issue of Compulsorily Convertible and Cumulative Preference Shares ("CCPSs")/Equity Share.

This is for your information and record.

Thanking You

Yours Truly,

For Vivimed Labs Limited


Santosh Varalwar
Managing Director & CEO

Encl: As above

VIVIMED LABS LIMITED
STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30th, 2011

(INR in mm)

Particulars	3 Months ended		12 Months Audited
	Unaudited	Audited	
	30-06-2011	30-06-2010	31-03-2011
1. (a) Net Sales/Income from Operations	1,039.30	542.61	3,098.10
(b) Other Operating Income	0.20	0.09	2.87
Total Income(1+2)	1,039.50	542.70	3,100.97
2. Expenditure			
a. (Increase) / decrease in stock in trade and work in progress	845.79	431.98	2,594.98
b. Consumption of Raw Materials	(6.60)	(28.45)	(44.50)
c. Purchase of Traded Goods	610.68	338.01	1,988.45
d. Employee Cost	-	-	-
e. Depreciation	28.82	16.16	105.39
f. Other Expenditure	14.12	8.63	50.31
g. Total	198.78	97.63	495.33
8. Total	845.79	431.98	2,594.98
3. Profit from Operations before Other Income, Interest and Exceptional items (1-2)	193.70	110.72	505.99
4. Other Income	-	-	-
5. Profit before Interest and Exceptional items (3+4)	193.70	110.72	505.99
6. Interest	58.65	35.33	176.31
7. Profit after Interest but before Exceptional items (5-6)	135.05	75.39	329.68
8. Exceptional items	-	-	-
9. Profit(+) / Loss(-) from ordinary activities before Tax (7+8)	135.05	75.39	329.68
10. Tax Expenses	27.02	12.29	52.05
11. Net profit(+) / Loss(-) from ordinary activities after Tax(9-10)	108.03	63.10	277.63
12. Extraordinary Items (net of tax expense Rs....)	-	-	-
13. Net Profit(+) / Loss(-) for period(11-12)	108.03	63.10	277.63
14. Paid-up Equity Share Capital (Face value of Rs 10/- each)	101.64	99.65	101.64
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-
16. Earning Per Share(EPS)			
a. Basic EPS before extraordinary items for the period, for the year to date and for the previous year	10.63	6.33	27.32
b. Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year	8.93	6.33	23.82



[Handwritten signature]

17. Public Shareholding			
- Number of shares	50,98,643	44,43,665	50,46,200
- Percentage of shareholding	50.16%	44.59%	49.65%
18. Promoters and Promoter Group Shareholding **			
a) Pledged / Encumbered			
- Number of shares	10,52,455	10,52,455	10,52,455
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	20.78%	19.06%	20.56%
- Percentage of shares (as a % of the total share capital of the company)	10.36%	10.56%	10.36%
b) Non - encumbered			
- Number of shares	40,12,918	44,68,784	40,65,361
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	79.22%	80.94%	79.44%
- Percentage of shares (as a % of the total share capital of the company)	39.48%	44.85%	40.00%

1. The above Standalone Results for the Quarter ended June 30th, 2011 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on August 13th, 2011.
2. During the quarter ended June 30th, 2011 company has received one investor's complaint. No complaint was pending at the beginning of the quarter or lying unsolved at the end of the quarter.
3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com
4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS

Place: Hyderabad
Date: 13/08/2011

(SANTOSH VARALWAR)
Managing Director & CEO



VIVIMED LABS LIMITED
CONSOLIDATED UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30th, 2011

Particulars	(INR in mm)		
	3 Months ended		12 Months
	Unaudited	Audited	Audited
	30-06-2011	30-06-2010	31-03-2011
1. (a) Net Sales/Income from Operations			
(b) Other Operating Income	1,205.41	849.84	4,160.01
Total Income(1+2)	0.83	0.09	9.33
2. Expenditure			
a. (Increase) / decrease in stock in trade and work in progress	1,206.24	849.93	4,169.34
b. Consumption of Raw Materials	985.61	693.41	3,410.76
c. Purchase of Traded Goods	(66.23)	(15.13)	(45.91)
d. Employee Cost	701.92	493.44	2,415.58
e. Depreciation	-	-	-
f. Other Expenditure	48.65	46.06	199.67
g. Total	26.46	19.49	91.46
8. Total	274.82	149.55	749.97
3. Profit from Operations before Other Income, Interest and Exceptional items (1-2)	985.61	693.41	3,410.76
4. Other Income	220.63	156.52	758.58
5. Profit before Interest and Exceptional items (3+4)	-	0.10	-
6. Interest	220.63	156.62	758.58
7. Profit after Interest but before Exceptional items (5-6)	65.07	37.55	205.96
8. Exceptional items	155.57	119.07	552.62
9. Profit(+)/ Loss(-) from ordinary activities before Tax (7+8)	-	-	-
10. Tax Expenses	155.57	119.07	552.62
11. Net profit(+)/Loss(-) from ordinary activities after Tax(9-10)	31.64	20.93	64.31
12. Extraordinary Items (net of tax expense Rs.....)	123.93	98.14	488.31
13. Net Profit(+)/Loss(-) for period(11-12)	-	-	-
14. Paid-up Equity Share Capital (Face value of Rs 10/- each)	123.93	98.14	488.31
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	101.64	99.65	101.64
16. Earning Per Share(EPS)	-	-	-
a. Basic EPS before extraordinary items for the period, for the year to date and for the previous year			
b. Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year	12.19	9.85	48.04
	10.24	9.85	41.90



(Signature)

17. Public Shareholding			
- Number of shares	50,98,643	44,43,665	50,46,200
- Percentage of shareholding	50.16%	44.59%	49.65%
18. Promoters and Promoter Group Shareholding **			
a) Pledged / Encumbered			
- Number of shares	10,52,455	10,52,455	10,52,455
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	20.78%	19.06%	20.56%
- Percentage of shares (as a % of the total share capital of the company)	10.36%	10.56%	10.36%
b) Non - encumbered			
- Number of shares	40,12,918	44,68,784	40,65,361
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	79.22%	80.94%	79.44%
- Percentage of shares (as a % of the total share capital of the company)	39.48%	44.85%	40.00%

1. The above Consolidated Unaudited Results for the Quarter ended June 30th, 2011 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on August 13th, 2011.
2. During the quarter ended June 30th, 2011 company has received one investor's complaint. No complaint was pending at the beginning of the quarter or lying unsolved at the end of the quarter.
3. Consolidated Financial Statements have been prepared in accordance with Accounting Standard 21 on "Consolidated Financial Statements" issued by The Institute of Chartered Accountants of India. Consolidated results are combined numbers of Vivimed Labs Ltd and its 100% Subsidiaries, Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (which includes financial data of its 100% subsidiary Vivimed Labs Europe Limited, UK) and Vivimed Labs USA Inc.
4. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com
5. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
6. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS

(SANTOSH VARALWAR)

Managing Director & CEO

Place: Hyderabad

Date: 13/08/2011



**VIVIMED LABS LIMITED - CONSOLIDATED
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE
LISTING AGREEMENT**

(INR in mm)

Particulars	3 Months ended		12 Months ended	
	Unaudited		Audited	
	30-06-2011	30-06-2010	31-03-2011	31-03-2010
1. Segment Revenue (Net Sales/Income from each segment should be disclosed under this head)				
a. Speciality Chemicals Business	1,025.17	1,283.16	3,729.00	2,932.65
b. Pharma Business	377.85	178.22	997.24	819.98
Total	1,403.03	1,461.38	4,726.24	3,752.63
Less : Inter Segment Revenue	197.62	611.54	566.23	317.77
Net sales / Income from Operations	1,205.41	849.84	4,160.01	3,434.86
2. Segment Results(Profit)(+)/Loss(-) before tax and interest from each segment				
a. Speciality Chemicals Business	150.42	121.07	593.20	436.15
b. Pharma Business	70.21	35.55	165.37	172.58
Total	220.63	156.62	758.58	608.73
Less: 1. Interest	65.07	37.55	205.96	212.27
2. Other Un-allocable Expenditure net off	-	-	-	-
3. Un-allocable Income	-	-	-	-
Total Profit Before Tax	155.57	119.07	552.61	396.45
3. Capital Employed (Segment Assets - Segment Liabilities)				
a. Speciality Chemicals Business	4,953.04	3,552.47	4,783.87	3,678.69
b. Pharma Business	678.91	528.72	595.19	402.71
Total	5,631.95	4,081.18	5,379.06	4,081.40

Place : Hyderabad
Date : 13 / 08 / 2011

For Vivimed Labs Limited
(Santosh Varalwar)
Managing Director & CEO

